Clear2Cure is a biotech spin-off from Utrecht University developing Clearbodies®, a novel class of antibody-derived therapeutics that actively degrade disease-causing molecules. Instead of just blocking targets, Clearbodies® capture harmful proteins and direct them to abundant membrane proteins like EGFR, leading to their breakdown in lysosomes.

This immune-independent approach leverages small, stable nanobodies (VHHs), enabling easier production, lower immunogenicity, and broad applications—particularly against pathogens and toxic proteins that conventional antibodies and traditional drugs struggle with.

A patent for Clearbodies® was filed in 2022, and Clear2Cure B.V. was incorporated in 2023 to advance this technology. The company is particularly interested in viruses and IL-6 and is open to partnerships on other promising targets, including toxins, cytokines, autoantibodies, and neurodegenerative protein aggregation diseases.

Are you also interested to pitch your company at the next edition of Health~Holland Global Investor Forum and Innovation for Health on 10-11 March 2027 in Utrecht, the Netherlands? Then sign up for the event newsletter to stay informed.